Olin Biotech announced that the company signed an agreement with Science Park Trading in December 2023 and commissioned it to exclusively promote the AC conjugate vaccine nationwide from 2024 to 2026, with a total promotion task of 4 million doses. Recently, the two sides signed a supplementary agreement to optimize the cooperation period from January 1, 2024 to December 31, 2029. Other core provisions remain unchanged. The agreement is expected to have no significant impact on current results. In 2024, 252,000 doses of the vaccine will be sold, and there is uncertainty about the completion of promotion tasks and implementation of the agreement.

Olin Biotech announced that the company signed an agreement with Science Park Trading in December 2023 and commissioned it to exclusively promote the AC conjugate vaccine nationwide from 2024 to 2026, with a total promotion task of 4 million doses. Recently, the two sides signed a supplementary agreement to optimize the cooperation period from January 1, 2024 to December 31, 2029. Other core provisions remain unchanged. The agreement is expected to have no significant impact on current results. In 2024, 252,000 doses of the vaccine will be sold, and there is uncertainty about the completion of promotion tasks and implementation of the agreement.